Palvella Therapeutics Publishes Comprehensive Review Article Titled Microcystic and Macrocystic Lymphatic Malformations: Distinct Genetics And Clinical Strategies
Benzinga Newsdesk 7 months ago
News
Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare
Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the publication of a comprehensive review article in the Journal of Vascular Anomalies (JoVA) titled "Microcystic and Macrocystic Lymphatic Malformations: Distinct Genetics and Clinical Strategies."